CoChat
Sign Up
Cited by 86Toxoplasma gondii Research StudiesImmunotherapy and Immune ResponsesCoccidia and coccidiosis research

The DOI matches its Crossref record.

Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice

Golkar, Majid, Shokrgozar, Mohammad-Ali, Rafati, Sima, Musset, Karine, Assmar, Mehdi, Sadaie, Reza, Cesbron-Delauw, Marie-France, Mercier, Corinne·2007·Vaccine
DOI 10.1016/j.vaccine.2007.02.057
Open this paper in CoChat — free account

Abstract

To investigate the vaccine potential of both the Toxoplasma GRA2 and GRA6 antigens, the full length recombinant proteins were produced in Escherichia coli, formulated in MPL adjuvant, and used alone and in combination ("mix"), to immunize CBA/J mice. Although high ratios of specific IgG2a/IgG1 were measured against both proteins, only spleen cells from GRA2-immunized mice and mix-immunized mice produced high amounts of both IFN-gamma and IL-2 upon induction with Toxoplasma gondii Excretory-Secretory Antigens. Intra peritoneal challenge with Toxoplasma cysts resulted in significant reduction of brain cysts in GRA2- and in mix-vaccinated mice only. This study shows the protective efficacy of recombinant GRA2 against chronic infection by T. gondii and confirms the utility of MPL adjuvant in enabling a vaccine candidate to induce a protective Th1 immune response.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2007.02.057

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 48

  1. Mamidi, 2002, Central nervous system infections in individuals with HIV-1 infection, J Neurovirol, 8, 158, 10.1080/13550280290049723 · DOI
  2. Fayer, 2004, Zoonotic protozoa: from land to sea, Tends Parasitol, 20, 531, 10.1016/j.pt.2004.08.008 · DOI
  3. Sher, 2003, Induction and regulation of IL-12- dependent host resistance to Toxoplasma gondii, Immunol Res, 27, 5221, 10.1385/IR:27:2-3:521 · DOI
  4. Suzuki, 1988, Interferon-γ: the major mediator of resistance against Toxoplasma gondii, Science, 240, 516, 10.1126/science.3128869 · DOI
  5. Sayles, 2000, B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii, Infect Immun, 68, 1026, 10.1128/IAI.68.3.1026-1033.2000 · DOI
  6. Johnson, 2002, Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice, Infect Immun, 70, 185, 10.1128/IAI.70.1.185-191.2002 · DOI
  7. Alexander, 1996, Immunological control of Toxoplasma gondii and appropriate vaccine design, Curr Top Microbiol Immunol, 219, 188
  8. McAllister, 2005, A decade of discoveries in veterinary protozoology changes our concept of “subclinical” toxoplasmosis, Vet Parasitol, 132, 241, 10.1016/j.vetpar.2005.07.003 · DOI
  9. Parmley, 2002, Protective effects of immunization with a recombinant cyst antigen in mouse models of infection with Toxoplasma gondii tissue cysts, J Infect Dis, 185, S90, 10.1086/338464 · DOI
  10. Buxton, 1995, A commercial vaccine for ovine toxoplasmosis, Parasitol, 110, S11, 10.1017/S003118200000144X · DOI
  11. Couper, 2003, DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission, Vaccine, 21, 2813, 10.1016/S0264-410X(03)00163-4 · DOI
  12. Ismael, 2003, The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis, Infect Immun, 71, 6222, 10.1128/IAI.71.11.6222-6228.2003 · DOI
  13. Letscher-Bru V, Pfaff AW, Abou-Bacar A, Filisetti D, Antoni E, Villard O, JP et al. Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice. Infect Immun 2003;71:6615–6619. · DOI
  14. Martin, 2004, Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis, Clin Diagn Lab Immunol, 11, 704, 10.1128/CDLI.11.4.704-710.2004 · DOI
  15. Mévelec, 2005, Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice, Vaccine, 23, 4489, 10.1016/j.vaccine.2005.04.025 · DOI
  16. Lourenço, 2006, Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii, Microbes Infect, 8, 1244, 10.1016/j.micinf.2005.11.013 · DOI
  17. Mercier, 2005, Dense granules: are they key organelles to help understand the parasitophorous vacuole of all Apicomplexa parasites?, Int J Parasitol, 35, 829, 10.1016/j.ijpara.2005.03.011 · DOI
  18. Hughes, 1982, Characterisation of a secretory antigen from Toxoplasma gondii and its role in circulating antigen production, Int J Parasitol, 12, 433, 10.1016/0020-7519(82)90073-X · DOI
  19. Asai, 1987, Detection of nucleoside triphosphate hydrolase as a circulating antigen in sera of mice infected with Toxoplasma gondii, Infect Immun, 55, 1332, 10.1128/IAI.55.5.1332-1335.1987 · DOI
  20. Hassl, 1990, Detection and characterization of circulating antigens in acute experimental infections of mice with four different strains of Toxoplasma gondii, Zentralbl Bakteriol, 272, 526, 10.1016/S0934-8840(11)80054-X · DOI
  21. Mercier C, Cesbron-DelauwMF, Ferguson DJP. Dense granules of the infectious stages of Toxoplasma gondii: Their central role in the host/parasite relationship. In: Soldati D, Ajioka J, editors. Toxoplasma: Molecular and Cellular Biology. Horizon Scientific Press 2007, in press.
  22. Scorza, 2003, A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection, Infect Immun, 71, 309, 10.1128/IAI.71.1.309-316.2003 · DOI
  23. Bivas-Benita, 2003, Generation of Toxoplasma gondii GRA1 protein and vaccine loaded chitosan particles: preparation, characterization and preliminary in vivo studies, Int J Pharm, 266, 17, 10.1016/S0378-5173(03)00377-6 · DOI
  24. Murray, 1993, Multiple B-cell epitopes in a recombinant GRA2 secreted antigen of Toxoplasma gondii, Appl Parasitol, 34, 235
  25. Golkar, 2004, High-level expression and evaluation of the antigenicity of a recombinant Toxoplasma gondii GRA2 protein, Iranian J Biotech, 2, 170
  26. Golkar M, Rafati S, Abdel-Latif MS, Brenier-Pinchart MP, Fricker-Hidalgo H, Sima BK, et al. The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: compariosn of sera collected in both France and Iran from pregnant women. Diagn Microbiol Infect Dis 2007, in press. · DOI
  27. Prigione, 2000, Infect Immun, 164, 3741
  28. Cesbron-Delauw, 1996, Role of secretory dense granule organelles in the pathogenesis of toxoplasmosis, Curr Top Microbiol Immunol, 219, 59
  29. Zenner, 1999, Protective immunity in the rat model of congenital toxoplasmosis and the potential of excreted-secreted antigens as vaccine components, Parasite Immunol, 21, 261, 10.1046/j.1365-3024.1999.00229.x · DOI
  30. Zhou, 2007, Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris, Parasitol Res, 100, 829, 10.1007/s00436-006-0341-6 · DOI
  31. Ferrandiz, 2004, Limited value of assays using detection of immunoglobulin G antibodies to the two recombinant dense granule antigens, GRA1 and GRA6 Nt of Toxoplasma gondii, for distinguishing between acute and chronic infections in pregnant women, Clin Diagn Lab Immunol, 11, 1016, 10.1128/CDLI.11.6.1016-1021.2004 · DOI
  32. Peyron, 2006, Serotyping of Toxoplasma gondii in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America), Microbes Infect, 8, 2333, 10.1016/j.micinf.2006.03.023 · DOI
  33. Gatkowska, 2006, Toxoplasma gondii: an evaluation of diagnostic value of recombinant antigens in a murine model, Exp Parasitol, 114, 220, 10.1016/j.exppara.2006.03.011 · DOI
  34. Persing, 2002, Taking toll: lipid A mimetics as adjuvants and immunomodulators, Trends Microbiol, 10, S32, 10.1016/S0966-842X(02)02426-5 · DOI
  35. Seeber, 1996, Escherichia coli beta-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii, Gene, 169, 39, 10.1016/0378-1119(95)00786-5 · DOI
  36. Darcy, 1988, Induction of a protective anti-body dependent response against toxoplasmosis by in vitro excreted/secreted antigens from tachyzoites of Toxoplasma gondii, Parasite Immunol, 10, 553, 10.1111/j.1365-3024.1988.tb00242.x · DOI
  37. Mercier, 1993, Toxoplasma gondii: molecular characterization of a dense granule antigen (GRA2) associated with the network of the parasitophorous vacuole, Mol Biochem Parasitol, 58, 71, 10.1016/0166-6851(93)90092-C · DOI
  38. Lecordier, 1995, Characterization of a dense granule antigen of Toxoplasma gondii (GRA6) associated to the network of the parasitophorous vacuole, Mol Biochem Parasitol, 70, 85, 10.1016/0166-6851(95)00010-X · DOI
  39. Dabrowski, 1999, Cloning, over-expression, and purification of the recombinant His-tagged SSB protein of Escherichia coli and use in polymerase chain reaction amplification, Protein Expr Purif, 16, 96, 10.1006/prep.1999.1044 · DOI
  40. Charif, 1990, Toxoplasma gondii: characterization and localization of antigens secreted from tachyzoites, Exp Parasitol, 71, 114, 10.1016/0014-4894(90)90014-4 · DOI
  41. Labruyère, 1999, Differential membrane targeting of the secretory proteins GRA4 and GRA6 within the parasitophorous vacuole formed by Toxoplasma gondii, Mol Biochem Parasitol, 102, 311, 10.1016/S0166-6851(99)00092-4 · DOI
  42. Rodriguez, 1985, Major surface protein of Toxoplasma gondii (p30) contains an immunodominant region with repetitive epitopes, Eur J Immunol, 15, 747, 10.1002/eji.1830150721 · DOI
  43. Parmley, 1993, Genomic and corrected cDNA sequence of the P28 gene from Toxoplasma gondii, Mol Biochem Parasitol, 57, 161, 10.1016/0166-6851(93)90253-T · DOI
  44. Lecordier, 2000, Enzyme-linked immunosorbent assays using the recombinant dense granule antigens GRA6 and GRA1 of Toxoplasma gondii for detection of immunoglobulin G antibodies, Clin Diagn Lab Immunol, 7, 607, 10.1128/CDLI.7.4.607-611.2000 · DOI
  45. Graham, 1993, Response to influenza infection in mice with a targeted disruption in the interferon γ gene, J Exp Med, 178, 1725, 10.1084/jem.178.5.1725 · DOI
  46. van den Broek, 1995, Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors, J Virol, 69, 4792, 10.1128/JVI.69.8.4792-4796.1995 · DOI
  47. Markine-Goriaynoff, 2000, IFN-γ-independent IgG2a production in mice infected with viruses and parasites, Int Immunol, 12, 223, 10.1093/intimm/12.2.223 · DOI
  48. Cha, 2001, Effects of specific monoclonal antibodies to dense granular proteins on the invasion of Toxoplasma gondii in vitro and in vivo, Korean J Parasitol, 39, 233, 10.3347/kjp.2001.39.3.233 · DOI

Cited by

Sorted by citations

Metadata

Authors
Golkar, M., Shokrgozar, M.-A., Rafati, S., Musset, K., Assmar, M., Sadaie, R., Cesbron-Delauw, M.-F., & Mercier, C.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Pasteur Institute of Iran (IR)
Corresponding author
Mercier, Corinne
ORCID
Venue
Vaccine
Publisher
Elsevier BV
Published
2007-05
Volume
25
Issue
21
Pages
4301-4311
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2007.02.057
OpenAlex
W2054519950
Cited by
86
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 7 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 8
FWCI
4.84
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Centre National de la Recherche Scientifique
  • Pasteur Institute of Iran
Topics
  • Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Coccidia and coccidiosis research
Keywords
Toxoplasma gondii, GRA2, GRA6, recombinant protein vaccine, chronic toxoplasmosis, Th1 response, interferon-gamma, interleukin-2, excretory-secretory antigens, brain cysts, vaccine efficacy
MeSH terms
Adjuvants, Immunologic, Animals, Antibodies, Protozoan, Antigens, Protozoan, Brain, Disease Models, Animal, Escherichia coli, Humans, Lipid A, Mice, Inbred CBA, Toxoplasma, Toxoplasmosis, Animal, Vaccines, Synthetic, Protozoan Proteins, Protozoan Vaccines, Cytokines, Th1 Cells, Vaccines, Subunit, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review